PROTEK GC is in top 50 largest Russian companies
Based on the 2016 results PROTEK GC took the 49th line in the RBC 500: Russian Business Rating annual survey. Compared to 2015, the company rose by 6 points, having increased its revenue by 24% to 241 billion rubles.
Only two Russian pharmaceutical companies: PROTEK Group - No. 49 and NPK Katren - No. 50 entered top 50 companies.
“PROTEK GC rose from 55th to 49th line and became the largest company among Russian pharmaceutical companies by the results of 2016. High performance reflects the revenue growth exceeding the market averages in all segments of the Group: Distribution (+ 25.4%), Retail (32.5%), Production (23.2%)”, - commented Vadim Muzyaev, the President of Protek Group of Companies.
About the rating:
The parent companies of operating holdings that prepare consolidated statements, which reflect the indices of both the parent company and its subsidiaries participate in the rating.
The following companies are considered as Russian:
· Companies registered in Russia and owned by Russian individuals and legal entities (with at least 50% share);
· Companies registered in foreign jurisdictions, so called shell corporations, most of assets of which are located in Russia, and which are owned by Russian individuals and legal entities;
· Russian legal entities and foreign shell companies, most of assets of which are located in Russia, and which are owned by non-strategic foreign investors.
The main indicator of the companies’ rating is revenue net of VAT, excises and export duties (net revenue).
Upon results of 9 months of the year 2017 ProApteka is the leader of pharmacy unions
According to the analysts’ data, the union share at pharmaceutical market amounted to 3.63%. more...
CV PROTEK became the leader of pharmaceutical distributors rating for 9 months 2017
Upon results of 1-3 quarter 2017, сombined share of three major distributors amounted to 48.5 %, 18% thereof ac... more...
CV PROTEK launched My Health affordable care initiative
For project members the cost of pharmacological therapy drastically subsides due to sizable discounts for a wide rang... more...